Amgen’s Mvasi Biosimilar Survives Restraining Order Bid Again

US Appeals Court Denies Genentech Request For Injunction On Bevacizumab

Gavels
Amgen launched Mvasi on 18 July last year after Genentech was denied an injunction • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Legal & IP

More from Generics Bulletin